http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103372040-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2236-19 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-236 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-236 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 |
| filingDate | 2012-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103372040-B |
| titleOfInvention | Monas cuspurpureus Went Rhizoma Chuanxiong drug regimen of a kind of adjusting blood lipid and preparation method thereof |
| abstract | The object of the invention is pharmaceutical composition of open a kind of regulating blood lipid action (especially treating hypertriglyceridemia) and preparation method thereof; The object of the invention is also the pharmaceutical applications of openly described pharmaceutical composition.In pharmaceutical composition of the present invention, Monas cuspurpureus Went and the mutual compatibility of Rhizoma Chuanxiong, create potentiation.There is dehumidifying eliminate the phlegm, blood circulation promoting and blood stasis dispelling, effect of strengthening the spleen to promote digestion; Blood cholesterol, high density lipoprotein increasing can be reduced, reduce low density lipoprotein, LDL content, show the effect reducing triglyceride especially highlightedly, significantly can treat hypertriglyceridemia.Preparation technology of the present invention is reasonable, has both improve the content of effective ingredient lovastatin in Monas cuspurpureus Went, and has remained again the active component of each medicine in prescription, and given full play to the effect of each medicine.Invention formulation is using lovastatin content as quality control index, and the quality of the pharmaceutical preparations is stable, controlled. |
| priorityDate | 2012-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 55.